Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial
Roche plans to test if mixing its anti-inflammation drug Actemra with Gilead Sciences Inc's anti-viral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone, the Swiss drugmaker said on Thursday.
from Reuters: Health News https://reut.rs/36C9Hwp
https://bit.ly/2zwRqiM